Dried blood spots, pharmacokinetic studies and better medicines for children

Hitesh C Pandya1, Neil Spooner, Hussain Mulla

  • 1Department of Infection, Immunity & Inflammation, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Infirmary Square, Leicester, UK. hp28@le.ac.uk.

Bioanalysis
|April 2, 2011
PubMed

Insights

Measuring drug levels in children is difficult due to small blood sample needs. Dried blood spot sampling offers a promising solution for pediatric pharmacokinetic-pharmacodynamic data collection, improving drug safety and efficacy.

Area of Science:

  • Pediatric pharmacology
  • Analytical chemistry

Background:

  • Accurate measurement of circulating drug concentrations is crucial for developing safe and effective pediatric dosing regimens.
  • Current methods often require large blood volumes, posing a challenge for pediatric populations.

Purpose of the Study:

  • To discuss the potential of dried blood spot sampling as a method for obtaining pharmacokinetic-pharmacodynamic data in children.
  • To address the limitations of traditional blood sampling in pediatric drug development.

Main Methods:

  • Review of existing literature on dried blood spot sampling techniques.
  • Discussion of the advantages of dried blood spot sampling for pediatric studies.

Main Results:

  • Dried blood spot sampling allows for the use of small blood volumes, suitable for pediatric patients.
  • This method facilitates easier sample collection, storage, and transportation.

Conclusions:

  • Dried blood spot sampling presents a viable and advantageous approach to overcome challenges in pediatric drug concentration determination.
  • The adoption of dried blood spot sampling can significantly aid in optimizing pediatric dosing regimens for improved therapeutic outcomes.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...